Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of guselkumab in fistulizing perianal Crohn's disease
2023-504740-33-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 23
01
Overview
Phase 3, randomised trial in Crohn's disease and anal fistula comparing Guselkumab with Placebo (2 arms). Primary endpoint: Combined fistula remission at Week 24. Planned start Nov 2022; status: authorised.
02
Drugs
guselkumab
03
Conditions
Crohn's diseaseanal fistula
Beyond the preview
Go deeper on 2023-504740-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504740-33-00.